Narek Dshkhunyan is the CEO and co-founder of SANSO, a biomanufacturing startup aiming to make biologics more accessible to patients worldwide. Sanso was created to commercialize the microporous water technology out of Jarad Mason's lab at Harvard, a novel solution to dramatically increase the oxygen capacity of most aqueous solutions. Previously, Narek was a computational biologist at 10x Genomics, developing algorithms for groundbreaking single-cell and spatial transcriptomics products. Before that, he was a bioinformatics intern at Illumina. Narek holds an MEng and BSc in computer science and molecular biology from MIT.Núria Puigmal Dominguez, PhD, is an entrepreneur and cross-disciplinary bioengineer with expertise in biomaterials and immunology. Núria is passionate about developing patient-centered therapies that are portable and easy-to-use. Her post-doctoral research was conducted at Harvard Medical School; the Wyss Institute at the Harvard University; and the Institute for Medical Engineering and Science (IMES) at MIT, where she engineered drug delivery systems in collaboration with pharmaceutical companies such as Takeda Pharmaceuticals and Johnson & Johnson. She has authored multiple high-impact publications and is the inventor of several patents leveraging the use of biomaterials for drug delivery and diagnosis. During her fellowship, Núria will serve as a founding scientific member to translate into the market a microneedle patch for the management of autoimmune skin diseases. Núria holds a MS in biotechnology and a PhD in bioengineering from IQS School of Engineering in Barcelona, Spain.

Aaron Edwards is the co-founder and CEO of KiraGen Bio, a biotech company that utilizes machine learning-driven multiplex gene editing to engineer CAR-T cells that can resist the immunosuppressive effects of solid tumor microenvironments. With extensive experience in the biotechnology industry, including notable roles at Novartis Vaccines, bluebird bio, and Beam Therapeutics, where he led in vitro biology for their clinical CAR-T program for T cell leukemias (BEAM-201), Aaron is dedicated to spending his year as a fellow advancing KiraGen's lead initiatives against non-small cell lung cancer and glioblastoma multiforme. He is committed to building a team that embodies scientific excellence and emotional intelligence, with the goal of translating innovative research into therapies that significantly improve patient outcomes. Aaron also holds a strong belief in aligning business practices with the greater good, positioning KiraGen Bio to create substantial value for all stakeholders.

Stephen Linderman is the CEO and co-founder of Absco Therapeutics (AbscoTx), an immune oncology company specializing in image-guided, intratumoral drug delivery. AbscoTx is based on research from Professor Gio Traverso’s lab at MIT and interventional radiology at Massachusetts General Hospital. Steve is an internal medicine clinician at Beth Israel Deaconess Medical Center, an engineer with expertise in immune modulation and biomaterials, and an entrepreneur passionate about advancing patient care through targeted drug delivery. As a fellow, Steve will expand the AbscoTx platform, conduct intratumoral pharmacokinetic and toxicology studies, and establish proof of concept of large-animal, image-guided delivery. Steve previously worked at Third Rock Ventures leading company building in cellular engineering, which became Abata Therapeutics. He founded the nonprofit biotechnology incubator Sling Health during his MD/PhD at Washington University in St. Louis. Steve holds a master's in drug development from the University of Cambridge, where he was a Churchill Scholar. He completed residency training at Emory University and a postdoctoral fellowship with Professor Andrés García at Georgia Tech.Luca Giani (MPP 2022) is the co-founder and CEO of Ilios Therapeutics, a platform chemistry startup developing first-in-class small molecules modulating multiple complementary mechanisms involved in neurodegenerative diseases. Driven by personal and family experiences, Luca is dedicated to advancing brain-related disease research. As a fellow, Luca will be focusing on confirming Ilios Tx’s mechanism of action through in-vitro experiments and animal models. Luca previously served as a TAPP Fellow at the Harvard Belfer Center, researching under Dr. Bob Langer's mentorship on how to improve neurodegenerative disease research towards impact. A Forbes 30 Under 30 honoree, Luca holds an MPP from the Harvard Kennedy School and a BS from Georgetown University.

Somani Patnaik is the co-founder and CEO of TurnipCare, an AI-based referral management and care coordination platform aimed at simplifying specialist referral pathways and addressing inefficiencies that result in over $300 billion in lost value annually. Inspired by her personal experience navigating a high-risk pregnancy during her time at HBS, Somani is committed to developing TurnipCare into a comprehensive disease intelligence and personal care advisor platform, improving healthcare access and outcomes on a broad scale. Before HBS, Somani spent 10 years in the industry, managing software development teams building machine learning platforms at Oracle and Amazon Alexa. She holds bachelor's and master's degrees in EECS from MIT.

Andrew Thomson is co-founder and CEO of Modulate Bio, a biotechnology company developing next-generation therapies to treat neurological disorders, including tremors, epilepsy, and anxiety. Driven by personal and family experiences, Andrew is dedicated to advancing brain-related medicines. As a fellow, Andrew will be growing Modulate Bio’s drug discovery platform, focused on developing novel small molecule GABAa positive allosteric modulators (PAMs) with improved efficacy and safety. Andrew was previously a life sciences consultant at Charles River Associates, team lead with Social Venture Partners Boston, and holds a BA in biology from Brown University.

In addition to his work at HBS, Peter is a Partner at Atlas Venture, an early stage life science venture capital firm. Since 2002, Peter has been involved in the creation of several novel therapeutic and drug discovery platform companies. Prior to Atlas he was co-founder, executive vice president, and chief business officer of Celera Genomics, and held senior management positions at Applera. Peter is currently chairman of Obsidian Therapeutics, Zafgen, Cadent Therapeutics, and Synlogic and sits on the boards of Indalo and Perkin Elmer.

Peter received a BS in chemistry from Lowell Technological Institute (now known as the University of Massachusetts, Lowell) and a PhD in analytical chemistry from Northeastern University. He also completed Harvard Business School’s Program for Management Development.